Skip to content
Home/Companies/Biotech/Alchemab Therapeutics
AT

Alchemab Therapeutics

Biotech·UK·Active·7yr hold

Alchemab Therapeutics is a biotech company, headquartered in UK.

Entry
2019
Hold
7yr
Status
Active
Est. EV
–

Who owns Alchemab Therapeutics?

Alchemab Therapeutics is currently owned by SV Health Managers through SV7 Impact Medicine Fund (2019 vintage), since 2019.

Hand-verified · updated 2026-07-16

SV Health Managers
Investor
SV Health Managers
SV7 Impact Medicine Fund · 2019 · Life Sciences VC

Key facts

HQUK
SectorBiotech
StatusActive

More from SV7 Impact Medicine Fund

Other portfolio companies in the same fund.

AdvanCell
Active
BiotechAustralia· 2025
Draig Therapeutics
Active
BiotechUK· 2025
Prilenia Therapeutics
Active
BiotechNetherlands· 2022
Rondo Therapeutics
Active
BiotechUnited States· 2022
EyeBio
Exited 2024
BiotechUK· 2021
to
Mestag Therapeutics
Active
BiotechUK· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
2NA FISH
Active
Gruenderfonds RuhrGermany· 2026
Adcendo
Active
Jeito CapitalDenmark· 2026
Data refreshed weekly · Sourced from public filings